Kyverna Therapeutics (NASDAQ:KYTX) Earns Buy Rating from HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 218.07% from the stock’s previous close.

A number of other research firms have also issued reports on KYTX. JPMorgan Chase & Co. dropped their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.00.

Kyverna Therapeutics Stock Performance

KYTX traded down $0.04 during trading on Wednesday, hitting $7.86. 236,253 shares of the stock were exchanged, compared to its average volume of 871,952. The firm has a market capitalization of $477.81 million, a P/E ratio of -2.40 and a beta of 1.95. Kyverna Therapeutics has a 1-year low of $2.52 and a 1-year high of $13.67. The stock has a fifty day moving average price of $9.03 and a two-hundred day moving average price of $8.52. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. As a group, sell-side analysts predict that Kyverna Therapeutics will post -2.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC grew its holdings in Kyverna Therapeutics by 33.3% during the first quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock worth $17,260,000 after acquiring an additional 500,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Kyverna Therapeutics by 16.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after acquiring an additional 250,418 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Kyverna Therapeutics during the fourth quarter worth $15,667,000. Vanguard Group Inc. grew its holdings in Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after acquiring an additional 9,858 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Kyverna Therapeutics during the fourth quarter worth $9,220,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.